Chinese Medicine: Subsidiary of Fumarsoracetic acid fulnola biochemical raw material drugs approved for listing

On August 13th, the Chinese pharmaceutical company announced that its wholly-owned subsidiary Tianfang Pharmaceutical has received the approval and issuance of the Market Authorization Approval Letter for Fumaric Folic Acid from the National Medical Products Administration. This drug is mainly used to treat reflux esophagitis, and can be used in combination with appropriate antibiotics to eradicate Helicobacter pylori. In addition, Tianfang Pharmaceutical recently received the European Medicines Agency's approval and issuance of the Certificate of Suitability of the European Pharmacopoeia for Clindamycin Phosphate. This drug is a lincosamide antibiotic mainly used for Gram-positive bacteria and anaerobic bacteria infections.